Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
AbbVie Biotech Ventures
company
About
AbbVie Biotech Ventures, an Illinois-based company, makes investments in emerging biotech and pharmaceutical companies.
- 10001 - max
Highlights
Details
- Industries
- Biotechnology,Financial Services,Venture Capital
- Founded date
- Jan 1, 2013
- Number Of Employee
- 10001 - max
- Operating Status
- Active
- Investor Type
- CVC,Venture Capital
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Investments
Number of Investments
Number of Lead Investments
11
3
AbbVie Biotech Ventures has made 11 investments. Their most recent investment was on
Nov 15, 2022, when Jnana Therapeutics raised $107M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Nov 15, 2022
Jnana Therapeutics
|
Series C | $107M | Biotechnology | — |
|
Aug 18, 2021
Jnana Therapeutics
|
Series B | $50M | Biotechnology | — |
|
Mar 1, 2021
Carisma Therapeutics
|
Series B | $12M | Biotechnology | — |
|
Jan 7, 2021
Carisma Therapeutics
|
Series B | $47M | Biotechnology | — |
|
Jan 11, 2020
PACT Pharma
|
Series C | $75M | Biotechnology | — |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
